New pharmacological strategies for the treatment of non-infectious Uveitis. A Minireview
Access noteAcceso Abierto
MetadataShow full item record
Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications. Currently, the standard of care for NIU includes the administration of corticosteroids (CS) as first-line agents, but in some cases a more aggressive therapy is required. This includes synthetic immunosuppressants, such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In those patients who become intolerant or refractory to CS and conventional immunosuppressive treatment, biologic agents have arisen as an effective therapy. Among the most evaluated treatments, TNF-alpha inhibitors, IL blockers, and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU.
Comisión Nacional de Investigación Cientifica y Tecnológica (CONICYT) CONICYT FONDEF IT17I0087 National Agency for Research and Development (ANID) grant Fondecyt de Iniciacion en Investigacion 11191215
Artículo de publicación ISIArtículo de publicación SCOPUS
Quote ItemFront Pharmacol. 2020; 11: 655.
The following license files are associated with this item: